에 대한 최신 뉴스 Doximity (NYSE:DOCS) 주식

Doximity

Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.

Large Cap

News

Movers

Trading Ideas

BIRK

CHWY

DOCS

KVYO

NBIX

TEVA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 테바 파마수티컬스(NYSE:TEVA)의 주식은 회사와 사노피 SA(NASDAQ:SNY)가 궤양성 대장염 및 크론병에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.

테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)

ALAB

AXON

COIN

HOOD

PLTR

RDDT

TSLA

이들 10개 대형주는 도널드 트럼프가 47대 대통령 선거에서 승리한 지난주에 가장 좋은 성과를 냈다. 1. 앱러빈(NASDAQ:APP)의 주식은 3분기 실적 발표 후 82.27% 급등했다. 여러 애널리스트들이 주가 전망을 상향 조정했다.

도널드 트럼프 승리 주(11월 4일-8일): 이들 10개 대형주는 가장 큰 폭의 상승 기록

Earnings

Guidance

Health Care

After-Hours Center

닥시미티(NYSE:DOCS)의 주식은 회사가 예상보다 좋은 2분기 재무 결과를 발표한 후 목요일 애프터 마켓 세션에서 37% 이상 급등했다. Q2 매출: 1억 3,683만 달러, 예상치 1억 2,715만 달러 대비 상회 Q2 조정 EPS: 30센트, 예상치 25센트 대비 상회

닥시미티의 주식은 강력한 2분기 실적을 발표한 후 시간외 거래에서 37% 이상 급등

Doximity Inc

Jared Kushner, son-in-law of former President&nbsp;Donald Trump, has made it clear that he is not involved in Trump&#8217;s political endeavors. This statement comes amid ongoing scrutiny over his business dealings and political connections.
What Happened: Kushner, who is married to Trump&#8217;s daughter Ivanka, emphasized his detachment from Trump&#8217;s political activities during a podcast interview on Friday. During a podcast episode with &#8220;The Best with Patrick O'Shaughnessy,&#8221; he said he informed investors in February about raising additional capital, ensuring them that his role would remain unchanged regardless of Trump&#8217;s political future.
Kushner stated, &#8220;I&nbsp;made very clear to them&nbsp;that in the event that&nbsp;Trump was elected, that they&nbsp;should not expect anything from&nbsp;me.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The secret service affectionately called <a href="https://twitter.com/jaredkushner?ref_src=twsrc%5Etfw">@jaredkushner</a> "the Mechanic" because he was constantly fixing problems behind the scenes. That's the theme of our convo: &#8211; Affinity Partners &#8211; real estate &amp; business &#8211; government &#8211; the next 4 years &#8211; more Enjoy! <a href="https://t.co/V9YeuNrxG4">pic.twitter.com/V9YeuNrxG4</a>
&mdash; Patrick OShaughnessy (@patrick_oshag) <a href="https://twitter.com/patrick_oshag/status/1870097179253072202?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/24/12/42594797/trump-wants-to-get-rid-of-the-debt-ceiling-30-year-treasury-bonds-fall-to-2024-lows-stocks-cut-gains?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Would &#8216;Lead The Charge&#8217; To Scrap Debt Ceiling: 30-Year Treasury Bonds Slide To 2024 Lows, Stocks Cut Gains</a>
Kushner&#8217;s investment firm, Affinity Partners, has secured commitments from significant investors, including the Saudi Public Investment Fund and the Qatar Investment Authority, since 2021. He highlighted that these commitments were made when Trump&#8217;s political future was still uncertain. Kushner, who played a pivotal role in the Abraham Accords, founded Affinity after serving as a senior White House adviser. He assured that the firm has proactively avoided conflicts, eliminating the need to raise capital for the next four years.
Kushner and Affinity Partners have yet to respond to <a href="https://pro.benzinga.com">Benzinga</a>&#8216;s queries.
Why It Matters: Kushner&#8217;s distancing from Trump&#8217;s political sphere is noteworthy given his previous involvement in political fundraising activities. In May, Kushner was reportedly r<a href="https://www.benzinga.com/news/24/05/38750997/trumps-son-in-law-back-in-political-arena-jared-kushner-reportedly-making-calls-to-potential-donors">eaching out to donors</a> to support Trump&#8217;s 2024 campaign. This shift in stance comes amid scrutiny over Affinity Partners&#8217; foreign investments, which have raised concerns about potential conflicts of interest. 
In September, Senate Finance Committee Chair Sen. Ron Wyden (D-Ore.) <a href="https://www.benzinga.com/government/24/09/41043869/trump-son-in-laws-pe-firms-client-agreement-creates-unprecedented-conflicts-of-interest-involving-pr">questioned the firm&#8217;s dealings </a>with foreign investors, including the Saudi Arabian sovereign wealth fund. Wyden&#8217;s letter highlighted the firm&#8217;s collection of $157 million in management fees from foreign investors without generating returns, suggesting possible compensation schemes involving U.S. political figures. 
Kushner&#8217;s distancing from <a href="https://www.benzinga.com/real-estate/24/11/41898236/the-kushners-real-estate-empire-now-surpasses-trumps-heres-how-it-grew-from-1-8-billion-to-7-1-billion-since-2016">Trump&#8217;s political activities</a> may be an effort to mitigate these concerns and focus on his business ventures, which have seen significant growth. As of November, the Kushner family&#8217;s real estate empire has expanded from $1.8 billion to $7.1 billion since 2016.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/12/42635765/mary-trumps-warning-donald-trumps-second-term-already-is-more-dangerous-than-the-first?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mary Trump Issues Stark Warning On Donald Trump's Return To Power: &#8216;His Second Term Already Is More Dangerous Than the First&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

General

Jared Kushner Distances Himself From Father In Law's Political Influence: 'In The Event That Trump Was Elected...They Should Not Expect Anything From Me'

Loop Capital analyst Yun Kim maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Buy and raises the price target from $45 to $60.

Price Target

Analyst Ratings

Loop Capital Maintains Buy on Klaviyo, Raises Price Target to $60

Damon Enters Securities Purchase Agreement With Streeterville Capital; Agreement Includes Pre-Paid Purchases Up To $10M

Further Strengthens and Scales Communications Technologies Platform; Significant Installed Base and Attractive Pipeline of Growth Opportunities
CHARLOTTE, N.C., Dec. 23, 2024 (GLOBE NEWSWIRE) -- SPX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) announced today that it has entered into a definitive agreement to purchase Kranze Technology Solutions, Inc. ("KTS"), a leader in digital interoperability and tactical networking solutions. Upon closing, KTS will become a part of SPX Technologies' Communication Technologies ("CommTech") platform, within its Detection &amp; Measurement segment.
Headquartered in Des Plaines, Illinois, KTS has developed a strong reputation for advanced digital interoperability and tactical networking solutions which integrate and distribute real-time information across multiple communications domains and platforms to enhance situational awareness, coordination, and tactical execution during operations. KTS has built trusted relationships with customers, particularly with the US Marine Corps, equipping KTS' products on numerous marquee platforms.
Under the terms of the agreement, SPX Technologies will purchase KTS and certain significant tax attributes for approximately $350 million in cash. KTS is anticipated to generate revenue of approximately $90 million for the full year 2025, with a segment income margin and revenue growth rate that are both modestly above the Detection &amp; Measurement segment average.

SPXC

SPX Technologies Announces Agreement To Purchase Kranze Technology Solutions And Certain Significant Tax Attributes For ~$350M In Cash

Loop Capital analyst Yun Kim maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Buy and raises the price target from $160 to $200.

DDOG

Loop Capital Maintains Buy on Datadog, Raises Price Target to $200

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">230.09</td>
<td align="right">1.18</td>
<td align="right">0.51</td>
<td>257</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">236.74</td>
<td align="right">0.78</td>
<td align="right">0.33</td>
<td>33.3K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">40.360000</td>
<td align="right">-0.430</td>
<td align="right">-1.06</td>
<td>1.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">75.660000</td>
<td align="right">-0.770</td>
<td align="right">-1.01</td>
<td>3.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">83.400000</td>
<td align="right">-0.740</td>
<td align="right">-0.88</td>
<td>23.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">79.340000</td>
<td align="right">-0.600</td>
<td align="right">-0.76</td>
<td>1.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">132.890000</td>
<td align="right">-0.930</td>
<td align="right">-0.70</td>
<td>5.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.210000</td>
<td align="right">-0.300</td>
<td align="right">-0.62</td>
<td>124.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">85.135691</td>
<td align="right">-0.444</td>
<td align="right">-0.52</td>
<td>121</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">137.580000</td>
<td align="right">-0.420</td>
<td align="right">-0.31</td>
<td>4.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">97.890000</td>
<td align="right">-0.070</td>
<td align="right">-0.08</td>
<td>333</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For December 23, 2024

Small Cap Consumer Research analyst Eric Beder reiterates a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) with a Buy and maintains $30 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on a.k.a. Brands Holding, Maintains $30 Price Target

<a href="https://www.microstrategy.com/press/microstrategy-acquires-5262-btc-achieves-btc-yield-of-73-ytd-now-holds-444262-btc_12-23-2024" title="https://www.microstrategy.com/press/microstrategy-acquires-5262-btc-achieves-btc-yield-of-73-ytd-now-holds-444262-btc_12-23-2024">https://www.microstrategy.com/press/microstrategy-acquires-5262-btc-achieves-btc-yield-of-73-ytd-now-holds-444262-btc_12-23-2024</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

MSTR

MicroStrategy Acquires 5,262 BTC And Achieves BTC Yield Of 47.4% QTD And 73.7% YTD; Now Holds 444,262 BTC

Loop Capital analyst Eric Beder maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Buy and raises the price target from $500 to $550.

MSFT

Loop Capital Maintains Buy on Microsoft, Raises Price Target to $550

Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025
TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA
Fibromyalgia affects more than 10 million adults in the U.S., who are mostly women
TNX-102 SL has the potential to be the first member of a new class of analgesic drugs for fibromyalgia and first new drug for its treatment in more than 15 years
NDA based on two statistically significant Phase 3 studies of TNX-102 SL for the management of fibromyalgia, in which TNX-102 SL was generally well tolerated
CHATHAM, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company) today announced that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for a decision on marketing approval for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia. TNX-102 SL is a non-opioid, centrally-acting analgesic. Fibromyalgia is a common chronic pain condition that affects mostly women.

Biotech

TNXP

Tonix Pharmaceuticals Announces PDUFA Goal Date Of August 15, 2025, For FDA Decision On U.S. Marketing Approval For TNX-102 SL For Fibromyalgia; NDA Based On Two Statistically Significant Phase 3 Studies Of TNX-102 SL For The Management Of Fibromyalgia, In Which TNX-102 SL Was Generally Well Tolerated

WIIM

IIPR

Innovative Industrial Properties shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

Swvl Holdings Corp ("Swvl" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWVL#NASDAQ">SWVL</a>), a leading technology provider of enterprise and government mobility solutions, is collaborating with Saudi Awwal Bank (SAB Bank) to launch its last-mile shuttle operations in Riyadh, Saudi Arabia. This initiative builds on the successful launch of the Riyadh Metro and aims to bridge first- and last-mile connectivity gaps, ensuring seamless access for SAB employees to the city's new metro system.
SAB Bank, one of Saudi Arabia's leading financial institutions, is leveraging Swvl's first- and last-mile shuttle services to streamline employee commutes. Swvl provides shuttle buses that connect SAB employees to and from the nearest metro stations, ensuring a smooth and enhanced transportation experience.
Powered by Swvl's proprietary technology, the first- and last-mile shuttle services are designed to address critical connectivity gaps between business hubs and metro stations. By integrating virtual stops, Swvl brings commuters closer to Riyadh Metro stations, eliminating the inconvenience of long walks and ensuring a smooth transition to and from the metro. This service plays a crucial role following the metro launch, as it enhances accessibility, encourages public transport adoption, and provides a reliable, convenient alternative to private vehicles.
The Riyadh Metro has officially commenced operations, marking a significant milestone in the city's urban mobility transformation. The phased launch began on December 1, 2024. This comprehensive network encompasses six lines, covering a total of 176 kilometers and featuring 85 stations, including four main stations. The Riyadh Metro is designed to provide a sustainable, reliable, and efficient alternative to private vehicles, aiming to reduce traffic congestion and enhance connectivity across the capital.

Global

SWVL

Swvl Is Collaborating With Saudi Awwal Bank To Provide Last-Mile Shuttle Services For SAB Bank Following Riyadh Metro Launch

CRNC

Cerence AI Reaffirms Q1 And FY 2025 Guidance Previously Disclosed With FY 2024 Results On November 21, 2024

Giftify, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFT#NASDAQ">GIFT</a>) (the "Company"), the owner and operator of leading digital platforms, CardCash.com and Restaurant.com, with a focus on incentives and rewards in retail, dining &amp; entertainment experiences, today announced that its previously announced registered direct offering with Craft Capital Management, LLC has been cancelled.
Giftify management decided to cancel the offering due to market conditions.

Offerings

GIFT

Giftify Cancels Registered Direct Offering Due To Market Conditions

&nbsp;Confirmed By Nasdaq Moot Letter; Further Hearing No Longer Required

MDAI

Spectral AI Regains Compliance With Nasdaq Listing Standards

Dividends

CION

Cion Investment Corporation Announced A Special Distribution of $0.05 per Share, Payable On January 27, 2025 To Shareholders Of Record On December 30, 2024

New Drug Application (NDA) is based on pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib that demonstrated durable responses and prolonged progression-free survival in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC)
If approved, taletrectinib represents a potential best-in-class treatment option for patients with advanced ROS1+ NSCLC
U.S. Food and Drug Administration (FDA) has assigned a target action date of June 23, 2025
Nuvation Bio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that the U.S. FDA has accepted the company's NDA for taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of advanced ROS1+ NSCLC (line agnostic). The U.S. FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025. Priority Review designation underscores the significant advancement taletrectinib may offer patients with ROS1+ NSCLC, for which there remains a high unmet need for new treatment options. Taletrectinib previously received Orphan Drug Designation and is the only ROS1 TKI currently in development that has received Breakthrough Therapy Designation from the U.S. FDA for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs.

NUVB

Nuvation Bio Announces The U.S. FDA Accepts For Priority Review Nuvation Bio's New Drug Application For Taletrectinib For The Treatment Of Advanced ROS1-Positive Non-Small Cell Lung Cancer

Additional $3.4M Possible From Warrant Exercises

VVOS

Vivos Therapeutics Announces $3.5M Registered Direct Offering Of 709,220 Shares Of Common Stock At $4.935

After a review of relevant portions of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"), as well as a review of various non-authoritative interpretations and guidance authored by certain major U.S. accounting firms regarding the FASB ASC, on December 20, 2024, the Company's management has concluded that U.S. Generally Accepted Accounting Principles ("GAAP") requires that a borrower's balance outstanding on a revolving line of credit be reflected as a current liability when the loan agreement includes provisions for both (i) a required lock box arrangement with a lender in which the borrower does not have the ability to avoid using working capital to repay the amounts outstanding, whether or not the borrower has the ability to re-borrow funds based on its regular borrowing base calculation in the ordinary course of business, and (ii) a "subjective acceleration clause" which is defined in accordance with GAAP to include loan provisions that permit the lender to accelerate the loan upon the occurrence of a "material adverse change".&nbsp;
The Company's management has further concluded that the classification as a current liability is required in accordance with GAAP even if (i) it is deemed that the "subjective acceleration clause" is not probable to be utilized by the lender within twelve months from the date of the balance sheet and (ii) the maturity date of the loan extends more than twelve months from the date of the balance sheet.

Optical Cable Corp Revises Loan Reporting to Align with Updated GAAP Guidelines

FibroBiologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN LTD. ("Yorkville"), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.
Yorkville agreed to advance to FibroBiologics the first $15 million available under the SEPA in three equal tranches to be evidenced by convertible promissory notes. The first tranche in the amount of $5 million was funded upon entry into the SEPA. Subject to the satisfaction of certain conditions, the second tranche of $5 million will fund after the filing of a registration statement covering the resale of the shares issuable to Yorkville under the promissory notes, and the third tranche of $5 million will fund following the effectiveness of the registration statement and receipt of shareholder approval in satisfaction of Nasdaq rules. FibroBiologics can sell an additional $10 million of its common stock to Yorkville, subject to Yorkville's consent and other conditions, while the convertible promissory notes remain outstanding.

Financing

FBLG

FibroBiologics Has Entered Into A Standby Equity Purchase Agreement With YA II PN LTD. To Sell Up To $25M In The Aggregate Of Its Common Stock To Yorkville Over The Course Of 2-Years

Doximity could benefit from RFK Jr. leading HHS: Jefferies

Diamond Hill Long-Short Strategy Fund Q3 2024 Market Commentary

Jefferies analyst Glen Santangelo maintained a Buy rating on Doximity (DOCS – Research Report) today and set a price target of $64.00. The company'...

Doximity (DOCS) Gets a Buy from Jefferies

Mizuho initiated coverage of Doximity (DOCS) with a Neutral rating and $55 price target The company has witnessed some volatility in quarterly top-...

Doximity initiated with a Neutral at Mizuho

Polen U.S. Small Company Growth Q3 2024 Commentary

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

GE Vernova initiated, Merck upgraded: Wall Street's top analyst calls

In a report released on December 3, Stan Berenshteyn from Wells Fargo maintained a Hold rating on Doximity (DOCS – Research Report), with a price t...

Doximity Hold Rating: Balancing Strong Market Position with Political and Competitive Uncertainties

Doximity: Strong Fundamentals And Growth Potential Makes It Attractive

Stephens initiated coverage of Doximity (DOCS) with an Equal Weight rating and $55 price target Doximity runs the "leading digital platform for doc...

Doximity initiated with an Equal Weight at Stephens

In this video, I review the overall market. I also provide two new swing positions, along with my exact game plan for Monday's session.

Kick-Save And A Beauty; Two New Swing Positions

AFRM

ALEC

ALGN

ALIT

ALRM

AMZN

APPF

BROS

CIEN

COHR

CVNA

CWAN

DHIL

GDRX

GNRC

GSHD

HLNE

HSIC

LFMD

NSIT

NVEE

NVST

PCTY

PDCO

PGNY

PSTG

QLYS

RGEN

RMBS

ROAD

RVLV

SITM

SOLV

SSNC

TALK

TRMB

VEEV

VEON

XRAY

Legal

Press Releases

Kaskela Law LLC Announces Shareholder Investigation of Doximity, Inc. (NYSE: DOCS) and Encourages Long-Term DOCS Shareholders to Contact the Firm

DOXIMITY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties – DOCS

DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Mendaera Closes $73M Series B Financing to Scale Robotics and AI Across Mainstream Medical Procedures

DOXIMITY INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties – DOCS

Doximity to Release Fiscal 2025 Second Quarter Results on November 7, 2024

Doximity to Present at the Jefferies London Healthcare Conference

Doximity Announces Fiscal 2025 Second Quarter Financial Results

Doximity Report Confirms That Telemedicine Serves Key Role in Modern Health Care

Comments

Doximity

뉴스

에 대한 최신 뉴스 Doximity (NYSE:DOCS) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌